Singulex Inc., California-based developer and provider of Single Molecule Counting technology for clinical diagnostics and scientific discovery, announced that the Japanese Patent Office has granted a key patent covering methods for detecting or monitoring cardiovascular conditions by measuring the biomarkers cardiac Troponin-I (cTnI) and Interleukin 17-A (IL-17A) in highly sensitive assays.

Additionally, the Japanese patent claims one or more of Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-a), and various forms of B-type natriuretic peptides in combination with cTnI and IL-17A for detecting and monitoring the cardiovascular conditions.

Japanese Patent No. 5678045, entitled 'Highly Sensitive Biomarker Panels' provides patent protection in Japan through June 2029, and extends the company's portfolio of 22 issued patents related to its core SMC technology and biomarker assays. Singulex was previously granted United States Patent 8,450,069 that covers methods for assessing cardiovascular health and damage by measuring cTnI, IL-6, and IL-17A, along with one or more of TNF-a and BNP, in platform-independent highly sensitivity assays.

This patent provides Singulex exclusive US commercial rights in these assays and methods through June 2030. Similar patents are pending in numerous countries.